Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2007-01-29
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 408
- Registration Number
- NCT00428064
Efficacy and Safety of Sirolimus in LAM
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 89
- Registration Number
- NCT00414648
- Locations
- 🇯🇵
National Kinki-Chou Hospital, Sakai, Osaka, Japan
🇯🇵Niigata University Medical and Dental Hospital, Niigata, Japan
🇺🇸University of Texas Health Center at Tyler, Tyler, Texas, United States
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 11
- Registration Number
- NCT00411788
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Maastricht Radiation Oncology
- Target Recruit Count
- 44
- Registration Number
- NCT00409994
- Locations
- 🇳🇱
Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 304
- Registration Number
- NCT00406393
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 18
- Registration Number
- NCT00402415
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
Sirolimus for Autoimmune Disease of Blood Cells
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT00392951
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT00388362
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 146
- Registration Number
- NCT00382109
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
- Conditions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 17
- Registration Number
- NCT00374647
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.